Login to Your Account



Astellas to Pay $42M Up Front

NeurogesX's European Qutenza Deal Shifts Focus to U.S Filing

By Jennifer Boggs


Tuesday, June 23, 2009
With the PDUFA date for its capsaicin pain patch Qutenza (capsaicin 179 mg) rapidly approaching, NeurogesX Inc. gained a nice chunk of cash and squared away European rights to the product in a potential €105 million (US$145.5 million) deal with Astellas Pharma Inc. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription